Generic Viibryd Availability

Viibryd is a brand name of vilazodone, approved by the FDA in the following formulation(s):

VIIBRYD (vilazodone hydrochloride - tablet;oral)

  • Manufacturer: FOREST LABS INC
    Approval date: January 21, 2011
    Strength(s): 10MG [RLD], 20MG, 40MG

Has a generic version of Viibryd been approved?

No. There is currently no therapeutically equivalent version of Viibryd available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Viibryd. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Piperidines and piperazines
    Patent 5,532,241
    Issued: July 2, 1996
    Inventor(s): Bottcher; Henning & Seyfried; Christoph & Bartoszyk; Gerd & Greiner; Hartmut
    Assignee(s): Merck Patent Gesellschaft mit beschrankter Haftung
    Piperidine and piperazine derivatives of the formula I ##STR1## wherein Ind is an indol-3-yl radical which is unsubstituted or mono- or polysubstituted by OH, OA, CN, Hal, COR.sup.2 or CH.sub.2 R.sup.2, R.sup.1 is benzofuran-5-yl or 2,3-dihydrobenzofuran-5-yl, chroman-6-yl, chroman-4-on-6-yl, 3-chromen-6-yl or chromen-4-on-6-yl, which is unsubstituted or monosubstituted by CN, CH.sub.2 OH, CH.sub.2 OA or COR.sup.2, Q is C.sub.m H.sub.2m, N or CR.sup.3, A is alkyl having 1-6 C atoms, Hal is F, C1, Br or I, R.sup.2 is OH, OA, NH.sub.2, NHA or NA.sub.2, R.sup.3 is H, OH or OA and m is 2, 3 or 4, and their physiologically acceptable salts, are active on the central nervous system.
    Patent expiration dates:
    • September 29, 2019
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
    Patent 7,834,020
    Issued: November 16, 2010
    Inventor(s): Bathe; Andreas & Helfert; Bernd & Neuenfeld; Steffen & Kniel; Heike & Bartels; Matthias & Rudolph; Susanne & Böttcher; Henning
    Assignee(s): Merck Patent Gesellschaft
    The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation.
    Patent expiration dates:
    • June 5, 2022
      ✓ 
      Patent use: TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
    Patent 8,193,195
    Issued: June 5, 2012
    Inventor(s): Bathe; Andreas & Helfert; Bernd & Neuenfeld; Steffen & Kniel; Heike & Bartels; Matthias & Rudolph; Susanne & Böttcher; Henning
    Assignee(s): Merck Patentgesellschaft
    The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation.
    Patent expiration dates:
    • June 5, 2022
      ✓ 
      Patent use: TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
  • Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
    Patent 8,236,804
    Issued: August 7, 2012
    Inventor(s): Bathe; Andreas & Helfert; Bernd & Neuenfeld; Steffen & Kniel; Heike & Bartels; Matthias & Rudolph; Susanne & Böttcher; Henning
    Assignee(s): Merck Patentgesellschaft
    The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation.
    Patent expiration dates:
    • June 5, 2022
      ✓ 
      Patent use: TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
  • Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
    Patent 8,673,921
    Issued: March 18, 2014
    Assignee(s): Merck Patentgesellschaft
    The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypertension, cerebral disorders, chronic pain, acromegaly, hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation.
    Patent expiration dates:
    • June 5, 2022
      ✓ 
      Drug substance
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • January 21, 2016 -

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web1)